Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
3,5-Dimethoxybenzyl chloride → 1-(3,5-dimethoxybenzyl)-3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-5,5-dimethylimidazolidine-2,4-dione
참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|---|---|---|
| 반응물 | 3,5-Dimethoxybenzyl chloride | HCID 2758395 | — |
| 반응물 | 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-5,5-dimethylimidazolidine-2,4-dione | HCID 59524388 | — |
| 생성물 | 1-(3,5-dimethoxybenzyl)-3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-5,5-dimethylimidazolidine-2,4-dione | HCID 53375151 | — |
반응 단계
Prepared as in Example 12-16 from 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-5,5-dimethylimidazolidine-2,4-dione (Example 12-16a) and 1-(chloromethyl)-3,5-dimethoxybenzene. MS 454 (MH+). The title compound was shown to inhibit hT2R08 bitter receptor and had an IC50 of 0.3 μM.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| 특허 번호 | US09247759B2 |
| 출처 데이터셋 | uspto-grants-2016_02 |
| ORD ID | ord-4050126fa17349bfae0b6915cdfb021d |
| 출처 메모 | uspto-grants-2016_02 |